Gastrointestinal tolerability of nonsteroidal anti-inflammatory drugs

Drugs

Volumn 59, Issue SPEC. ISS. 1, 2000, Pages 17-23

  Bannwarth, Bernard ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 2 NAPHTHYLACETIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; ALKANONE;

BILIARY EXCRETION; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENTEROHEPATIC CIRCULATION; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; HUMAN; MACROPHAGE; MUCOSA CELL; NONHUMAN; PATHOGENESIS; PERFORATION; REVIEW; SYNOVIOCYTE; CHEMICALLY INDUCED DISORDER; ECONOMICS; GASTROINTESTINAL DISEASE; PATHOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUTANONES; CLINICAL TRIALS; GASTROINTESTINAL DISEASES; HUMANS;

EID: 0033649294     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059991-00003     Document Type: Review

References (23)

1. Committee on Safety of Medicines, Medicines Control Agency. Relative safety of oral non-apirin NSAIDs. Curr Probl Pharmacovigilance 1994; 20: 9-11
2. Champion GD, Feng PH, Azuma T, et al. NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia Pacific perspective and consensus. Drugs 1997; 53: 6-19
3. Roth SH. NSAID gastropathy. A new understanding. Arch Intern Med 1996; 156: 1623-8
4. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999; 340: 1888-99
5. Soll A. Pathogenesis of nonsteroidal anti-inflammatory drug-related upper gastrointestinal toxicity. Am J Med 1998; 105 Suppl. 5A: 10-6
6. La Corte R, Caselli M, Castellino G, et al. Prophylaxis and treatment of NSAID-induced gastroduodenal disorders. Drug Saf 1999; 20: 527-43
7. Wallace JL. NSAID gastroenteropathy: past, present and future. Can J Gastroenterol 1996; 10: 451-9
8. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999; 26 Suppl. 56: 18-24
9. Langman MJS. Risks of anti-inflammatory drug-associated damage. Inflamm Res 1999; 48: 236-8
10. Drummond M, Ferraz MB, Mason J. Assessing the cost effectiveness of NSAID: an international perspective. J Rheumatol 1995; 22: 1408-11
11. Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use nonsteroidal antiinflammatory drugs. Arthritis Rheum 1998; 41: 16-25
12. Hochberg MC. Association of nonsteroidal antiinflammatory drags with upper gastrointestinal disease: epidemiologic and economic considerations. J Rheumatol 1992; 19 Suppl. 36: 63-7
13. Mangan FR, Flack JD, Jackson D. Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology. Am J Med 1987; 83 Suppl. 4B: 6-10
14. Spangler RS. Gastrointestinal damage demonstrated with nabumetone or etodolac in preclinical studies. Am J Med 1993; 95 Suppl. 2A: 35-9
15. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993; 153: 2565-71
16. Roth SH, Bennett R, Caldron P, et al. A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. J Rheumatol 1994; 21: 1118-23
17. ® 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Clin Ther 1999; 21: 659-74
18. Fleischmann RM. Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis. J Rheumatol 1992; 19 Suppl. 36: 32-40
19. Lipani JA, Poland M. Clinical update of the relative safety of nabumetone in long-term clinical trials. Inflammopharmacology 1995; 3: 351-61
20. Bernhard GC. Worldwide safety experience with nabumetone. J Rheumatol 1992; 19 Suppl. 36: 48-57
21. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drags with continued exposure: cohort study. BMJ 1997; 315: 1333-7
22. Bannwarth B, Berenbaum F. Nouveaux anti-inflammatoires non stéroïdiens : donneurs de NO et inhibiteurs sélectifs de COX-2. Rev Med Int 1999; 20 Suppl. 3: 341-5
23. Spangler RS. Cyclooxygenase 1 and 2 in rheumatic diseases: implications for nonsteroidal drug therapy. Semin Arthritis Rheum 1996; 26: 435-46